Investigational Site Number : 0320002

Córdoba X5016KEH

1 studies enrolling now · 2 studies all time

What they study most

Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Plasma Cell Myeloma

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) — Completed